Article Text

Download PDFPDF
Primary pleural liposarcoma: a rare differential for an opaque hemithorax
  1. Avishek Layek1,
  2. Akhlesh Rajpoot1,
  3. Prashant Joshi2 and
  4. Mayank Mishra1
  1. 1Pulmonary Medicine, All India Institute of Medical Sciences, Rishikesh, Rishikesh, India
  2. 2Pathology & Laboratory Medicine, All India Institute of Medical Sciences, Rishikesh, Rishikesh, India
  1. Correspondence to Dr Mayank Mishra; virgodrmayank{at}gmail.com

Abstract

Primary pleural liposarcoma (PPL) is a rare primary malignant pleural tumour originating from primitive mesenchymal tissue. We report the case of a 25-year-old man with a 6-week history of shortness of breath, cough, chest pain and hoarseness of voice. Chest X-ray showed a left opacified hemithorax, and thoracic CT scan revealed a large, heterogeneous, hypodense mass in the left hemithorax. The patient was taken up for ultrasound-guided core biopsy of the mass lesion, and histopathological examination revealed the diagnosis as a pleomorphic variant of PPL. We highlight the importance of considering PPL as a differential diagnosis in cases of large hemithoracic masses.

  • respiratory medicine
  • oncology

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors Clinical data acquisition, literature review and initial manuscript draft: AL, AR. Manuscript editing, review, proof-reading and guarantor: MM. Histopathology and related literature review: PJ.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.